TheraCell Announces Delivery Of Over 25,000 Of Its Licensed Bone Fiber Grafts
Products Have Reached an Annual End Customer Sales Rate Approaching $30M
News provided by
Share this article
Share this article
LOS ANGELES, Dec. 17, 2020 /PRNewswire/ TheraCell Inc., a leading allograft solution company, today announced that over 25,000 of its licensed demineralized bone fiber products have been delivered by its licensee partners. TheraCell s partners have seen steady double-digit quarter over quarter growth, now representing an annual end customer sales rate approaching $30M.
(PRNewsfoto/TheraCell, Inc.)
TheraCell has licensed the base fiber technology to AlloSource to produce and market AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats, and to produce private label products to be marketed by other orthopedic companies. The technology has also been licensed to Australian Biotechnologies to produce and market AlloVance® Xpress Fibres, AlloVance® Xpress Hybrid, AlloVance®